82732-07-8

Basic information

• Product Name: Boc-D-homophenylalanine
• Synonyms: BOC-D-HOMOPHENYL-ALA;BOC-D-HOMOPHENYLALANINE;BOC-D-HOMOPHE-OH;BOC-D-HOPHE-OH;BOC-D-HFE-OH;BOC-HOMO-D-PHENYLALANINE;BOC-(R)-2-AMINO-4-PHENYLBUTYRIC ACID;2-tert-Butoxycarbonylamino-4-phenyl-butyric acid
• CAS NO: 82732-07-8
• Molecular Formula: C₁₅H₂₁NO₄
• Molecular Weight: 279.33
• Product Categories: Phenylalanine analogs and other aromatic alpha amino acids;Amino Acid Derivatives;PROTECTED AMINO ACID & PEPTIDES;Amino Acids
• Mol File: 82732-07-8.mol
• Article Data: 25

Chemical Properties

• Melting Point: 71-78℃
• Boiling Point: 439.6 °C at 760 mmHg
• Flash Point: 219.7 °C
• Appearance: White to off-white/Powder
• Density: 1.139
• Storage Temp.: Store at 0°C
• PKA: 3.95±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• BRN: 3653505
• CAS DataBase Reference: Boc-D-homophenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-D-homophenylalanine(82732-07-8)
• EPA Substance Registry System: Boc-D-homophenylalanine(82732-07-8)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 82732-07-8(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline

Uses

(R)-2-(Boc-amino)-4-phenylbutyric acid is an important raw material and intermediate used in organic synthesis, pharmaceuticals, agrochemicals and dyestuff fields.

Upstream product

• 115378-31-9 tert-butyl (4R)-2,2-dimethyl-4-vinyloxazolidine-3-carboxylate 
• 133625-99-7 (2R,3E)-2-(tert-butyloxycarbonylamino)-4-phenyl-3-buten-1-ol 
• 116696-85-6 (2S)-2-t-butoxycarbonylamino-3-phenylsulfonyl-1-(2-tetrahydropyranyloxy)propane 
• 1434253-83-4 C₂₁H₃₁NO₃S₂ 
• 1434253-82-3 C₁₁H₂₀INO₃ 
• 5425-44-5 2-Phenyl-[1,3]dithiane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 943-73-7 D-homophenylalanine 
• 116611-45-1 (2R)-2-t-butoxycarbonylamino-3-phenylsulfonyl-1-(2-tetrahydropyranyloxy)propane 
• 106860-17-7 methyl 2S-2-amino-4-phenylbutanoate 
• 92136-56-6 (2S)-[N-(tert-butoxycarbonyl)amino]-4-phenylmethyl butanoate 
• 872728-71-7 (2S,3R)-3-(tert-butoxycarbonylamino)-5-phenyl-1,2-pentanediol 
• 82795-51-5 (-)-2-amino-4-phenylbutyric acid 
• 116611-51-9 [(R)-2-Benzenesulfonyl-3-phenyl-1-(tetrahydro-pyran-2-yloxymethyl)-propyl]-carbamic acid tert-butyl ester 

Downstream Products

• 251308-37-9 [(2-tert-butoxycarbonylamino-4-phenyl-butyryl)-(3-phenyl-propyl)-amino]-acetic acid methyl ester 
• 162126-44-5 (3-phenyl-1-{[2'-(1-trityl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-carbamoyl}-propyl)-carbamic acid tert-butyl ester 
• 663948-78-5 [3-phenyl-1-(4-piperidin-1-yl-phenylcarbamoyl)-propyl]-carbamic acid tert-butyl ester 
• 92136-56-6 (2S)-[N-(tert-butoxycarbonyl)amino]-4-phenylmethyl butanoate 
• 254882-54-7 N-tert-butoxycarbonyl-D-homophenylalanine 3-quinolylamide 
• 246877-32-7 (tert-butoxycarbonyl)-homophenylalanyl-diethylamide 
• 162818-40-8 (S)-3-(<(tert-butoxy)carbonyl>amino)-1-diazo-5-phenylpentan-2-one 
• 110755-67-4 N-BOC-L-homophenylalanine-N-methylamide 
• 183444-03-3 tert-butyl (S)-(1-(methoxy(methyl)amino)-1-oxo-4-phenylbutan-2-yl)-carbamate 

Relevant articles and documents

Absolute Configuration of 2-Amino-4-phenylbutyric Acid (Homophenylalanine)

-

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

N-alkoxyamide conjugates as imaging agents

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.